SOPHiA GENETICS SA

Equities

SOPH

CH1125843347

Software

Market Closed - Nasdaq 04:30:01 2024-04-15 pm EDT 5-day change 1st Jan Change
4.86 USD -2.80% Intraday chart for SOPHiA GENETICS SA 0.00% +3.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sophia Genetics Forms Partnership With Strand Life Sciences to Advance Diagnostic Tools MT
Sophia Genetics SA Announces Laboratorio Barnafi-Krause Is Live on the Sophia DDM? Platform CI
SOPHiA GENETICS Announces First Homologous Recombination Deficiency Customer in Canada CI
Transcript : SOPHiA GENETICS SA, Q4 2023 Earnings Call, Mar 05, 2024
SOPHiA GENETICS SA Provides Earnings Guidance for 2024 CI
SOPHiA GENETICS SA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : S&P 500 Futures -2- DJ
Sophia Genetics, AstraZeneca Expand Project to Improve Access to Ovarian Cancer Testing in Spain MT
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain CI
Sophia Genetics Supports Genetic Testing in Brazil CI
SOPHiA GENETICS Enhances RareCyte Inc. Precision Biology Services Portfolio CI
SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India CI
Transcript : SOPHiA GENETICS SA Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:00 AM
SOPHiA GENETICS SA Provides Preliminary Earnings Guidance for the Full Year Ending December 31, 2023 CI
Exactis Innovation and SOPHiA GENETICS Announce Collaboration on Multimodal Data Analytics CI
SOPHiA GENETICS SA Announces Expanded Suite of Liquid Biopsy Offerings CI
Sophia Genetics Says CHU de Nimes Uses DDM Platform for Pharmacogenomics Research MT
Sophia Genetics Announces Expansion of Work with Chu De Nîmes CI
RBC Initiates SOPHiA GENETICS at Outperform With $8 Price Target, Notes 'Attractive' Entry Point, Exposure to Long-Term Growth in Sequencing, Life Science Research MT
Sophia Genetics Broadens Relationship With Italian Hospital MT
SOPHiA GENETICS Expands Relationship with Citta della Salute e della Scienza di Torino CI
Transcript : SOPHiA GENETICS SA, Q3 2023 Earnings Call, Nov 07, 2023
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM? CI
SOPHiA GENETICS SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
SOPHiA GENETICS SA Provides Earnings Guidance for the Year 2023 CI
Chart SOPHiA GENETICS SA
More charts
Sophia Genetics SA is a Switzerland-based company engaged in the software publishing sector. The Company offer a cloud-based Software-as-a-Service platform - the SOPHiA DDM, which is data-driven medicine platform enabling insights from disparate, complex datasets to improve diagnosis, treatment, and drug development. The Company has offices in Switzerland, France and the United Kingdom and operates worldwide.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.86 USD
Average target price
8.667 USD
Spread / Average Target
+78.33%
Consensus
  1. Stock Market
  2. Equities
  3. SOPH Stock
  4. News SOPHiA GENETICS SA
  5. SOPHiA GENETICS Partners With Agilent For Cancer Analysis Product